MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijcrp.2025.200526

Медицинская библиотека · International journal of cardiology. Cardiovascular risk and prevention · 2025

Comorbidity patterns and mortality in HFpEF: A retrospective longitudinal cohort study.

Yousufuddin Mohammed, Ma Zeliang, Barkoudah Ebrahim, Tahir Muhammad Waqas, Yazdanyar Ali, Chikkanna Rani, Benkhadra Khalid, Bhagra Sumit, Fonarow Gregg C, Yamani Mohamad H

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Comorbid conditions (CCs) in heart failure with preserved ejection fraction (HFpEF) are associated with poor prognosis, but the influence of their duration on mortality remains unclear. We examined how pre-admission comorbidity duration affects long-term mortality after HFpEF hospitalization.

METHODS

This retrospective study included adults hospitalized for HFpEF at 17 hospitals (2010-2022) with follow-up through July 2024. Twelve individual and four system-based comorbidities present at admission were classified by duration: new (<0.5 years), early (0.5-<3 years), intermediate (3-<6 years), and long-term (>6 years). Mortality was further stratified by Get With The Guidelines-Heart Failure (GWTG) score (1, 2, ≥3) and discharge SGLT2i prescription. Cox regression and restricted cubic splines estimated risk.

RESULTS

Among 9256 patients (mean age 77.8 years; 54.1 % female; 40.2 % rural), 64.1 % died over a median follow-up of 2.7 years. Comorbidity prevalence ranged from 6.0 % (neurological) to 73.4 % (hypertension), with durations from 0.5 years (obesity) to 5 years (diabetes). Most comorbidities increased mortality risk (HRs 1.06-1.25), highest for neurological disease, CKD, stroke, and anemia. Risk rose within 3 years of comorbidity onset, then stabilized, consistent across age, sex, and residential status. Associations persisted across GWTG strata. SGLT2i therapy attenuated mortality risk for most comorbidities, though residual risk remained for stroke, CKD, chronic lung, and neurological disease.

CONCLUSIONS

In HFpEF, comorbidities are common and associated with higher mortality, especially within the first 3 years. Prognostic effects persisted across GWTG strata, while SGLT2i therapy attenuated these risks, highlighting the importance of early detection and optimized therapy.

Для цитирования: Yousufuddin Mohammed, Ma Zeliang, Barkoudah Ebrahim, Tahir Muhammad Waqas, Yazdanyar Ali, Chikkanna Rani, Benkhadra Khalid, Bhagra Sumit, Fonarow Gregg C, Yamani Mohamad H. Comorbidity patterns and mortality in HFpEF: A retrospective longitudinal cohort study.. International journal of cardiology. Cardiovascular risk and prevention. 2025. DOI: 10.1016/j.ijcrp.2025.200526.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.